Tokyo Tape
Sign in
← Nipro

Quarterly report · Q1

8086.TEDINET S100RNZX
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥140.6bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥127.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥7.3bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥3.0bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥8.9bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.3bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥9.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥9.0bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥4.1bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥5.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥4.4bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥5.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥1.04Tat 2023-06-30Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥947.6bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥791.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥249.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥217.3bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥88.1bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥25.142023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥32.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥22.272023-04-01 → 2023-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥28.662022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio20.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio21.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥189m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥971m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥14.5bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥14.5bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥8.2bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-06-30¥109.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-06-30¥108.0bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-06-30¥11.8bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-06-30¥27.8bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-06-30¥17.4bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥10.3bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.2bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-06-30¥16.6bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.0bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-06-30¥566m
—segment totalrevenue2023-04-01 → 2023-06-30¥153.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥140.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥13.5bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥15.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥155.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥140.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥14.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥15.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥154m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥855m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥211m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.1bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥99.3bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥97.7bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥23.2bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥17.9bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥5.3bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥407m
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-06-30¥13.7bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-06-30¥12.2bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.0bn
—segment totalrevenue2022-04-01 → 2022-06-30¥136.2bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥127.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥8.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥137.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥127.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥10.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 446
ItemContextValueUnit
Net salesCurrentYTDDuration140594000000JPY
Cost of salesPrior1YTDDuration88685000000JPY
Cost of salesCurrentYTDDuration97530000000JPY
Gross profitPrior1YTDDuration39206000000JPY
Gross profitCurrentYTDDuration43063000000JPY
Selling general and administrative expensesPrior1YTDDuration36252000000JPY
Selling general and administrative expensesCurrentYTDDuration35726000000JPY
Operating incomePrior1YTDDuration2954000000JPY
Operating incomeCurrentYTDDuration7337000000JPY
Interest income noiPrior1YTDDuration248000000JPY
Interest income noiCurrentYTDDuration287000000JPY
Dividends income noiPrior1YTDDuration59000000JPY
Dividends income noiCurrentYTDDuration64000000JPY
Foreign exchange gains noiPrior1YTDDuration5070000000JPY
Foreign exchange gains noiCurrentYTDDuration2801000000JPY
Other noiPrior1YTDDuration628000000JPY
Other noiCurrentYTDDuration702000000JPY
Non operating incomePrior1YTDDuration6007000000JPY
Non operating incomeCurrentYTDDuration3857000000JPY
Interest expenses noePrior1YTDDuration1011000000JPY
Interest expenses noeCurrentYTDDuration1374000000JPY
Equity in losses of affiliates noePrior1YTDDuration274000000JPY
Equity in losses of affiliates noeCurrentYTDDuration391000000JPY
Other noePrior1YTDDuration338000000JPY
Other noeCurrentYTDDuration527000000JPY
Non operating expensesPrior1YTDDuration1624000000JPY
Non operating expensesCurrentYTDDuration2293000000JPY
Ordinary incomePrior1YTDDuration7337000000JPY
Ordinary incomeCurrentYTDDuration8901000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration1909000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration86000000JPY
Gain on sales of investment securities eiPrior1YTDDuration39000000JPY
Gain on sales of investment securities eiCurrentYTDDuration1742000000JPY
State subsidy eiPrior1YTDDuration－JPY
State subsidy eiCurrentYTDDuration367000000JPY
Other eiPrior1YTDDuration0JPY
Other eiCurrentYTDDuration201000000JPY
Extraordinary incomePrior1YTDDuration1949000000JPY
Extraordinary incomeCurrentYTDDuration2397000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration30000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration51000000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration－JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration161000000JPY
Provision of allowance for doubtful accounts elPrior1YTDDuration40000000JPY
Provision of allowance for doubtful accounts elCurrentYTDDuration－JPY
Expense for treatment of waste elPrior1YTDDuration70000000JPY
Expense for treatment of waste elCurrentYTDDuration－JPY
Dispute costs elPrior1YTDDuration118000000JPY
Dispute costs elCurrentYTDDuration50000000JPY
Loss on sale of investment in affiliated companies elPrior1YTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass